MLX.png

A portfolio of early-stage drug candidates produced using proprietary protein engineering technology.

Molecular LogiX (MLX) is a biotechnology company in the Texas Medical Center.  The Company has developed and patented several proteins that inhibit the growth of tumor cells implicated in the progression of drug-resistant tumors.  The proteins are “Dominant Negative Ligands” - variants of authentic human proteins that have been re-engineered from growth agonists into growth antagonists.  The technology was developed with investments from Baylor College of Medicine Technologies (BCMT), grants from the NIH, and in collaboration with investigators at BCM and the UT M D Anderson Cancer Center. 

The lead compound is a “Pan-HER DNL”, aimed at tumors that are resistant to currently available HER-targeting drugs, such as those in most cases of metastatic breast cancer.

Our Team

Daniel J. monticello, phd

Co-Founder & CSO.  Molecular biologist and serial biotechnology entrepreneur with 22 issued US patents in biotechnology, experience at large biotech (Bayer AG) and several start-ups.  He has received over $8 million in grant support and helped raise over $90 million in private and public investments. 

caroline popper, md

President, BCM Technologies (“BCMT”, the venture subsidiary of Baylor College of Medicine).  A co-founder of Popper and Company with over 20 years of hands-on biotech life sciences operating experience. Dr. Popper received her MD from the University of the Witwatersrand (South Africa) and her MPH from Johns Hopkins University (Baltimore). She completed her residencies in Internal Medicine and in Pathology at Johns Hopkins.   BCMT manages the interests of MLX.


Advisors & Collaborators

shane climie, phd

Scientific and Business Consultant

Timothy Palzkill, PhD

Chairman/Professor, Department of Pharmacology, Baylor College of Medicine

phillip t. pienkos, phd

Co-Founder.  Manager, Bioprocess R&D Group of the National Bioenergy Center, NREL

Zhiqiang An, PhD 

Professor and Director, Texas Therapeutics Institute, UT Health (UTHSC)

MOLECULAR LOGIX

6501 Fannin Street
Houston, TX 77030